Latest Content

Machine learning–based risk prediction models, particularly gradient boosting, can accurately identify early clinical indicators of CKD.

Elevance Health's Shane Hochradel explains how the company tracks provider satisfaction and uses AI to cut administrative burden.

Employers use carve-outs and cash-pay channels to reduce GLP-1 costs, while Scripta’s Navigator helps members compare prices and find support.

A prospective study of first-degree relatives of patients with MS found that this high-risk population faces significantly elevated incidence rates and has strong willingness to participate in prevention trials.

Mitochondrial DNA heteroplasmy is independently associated with an increased risk of CLL, suggesting potential as a novel biomarker for early risk identification.

Presentations focused on the efficacy of long-acting cabotegravir, doravirine/islatravir, and bictegravir/lenacapavir when used as antiretroviral therapy.

MASLD and type 2 diabetes are closely interconnected conditions driven by shared metabolic dysfunction that together increase the risk of liver disease progression, cardiovascular complications, and mortality.

Abstracts presented during the Conference on Retroviruses and Opportunistic Infections 2026 offered a glimpse into which therapies patients prefer to use to treat HIV.

The ready-to-use formulation supports clinicians and families by addressing historical administration challenges.